Regulation - North America, Sarepta Therapeutics

Filter

Popular Filters

Sarepta plunges as FDA questions eteplirsen trial results

Sarepta plunges as FDA questions eteplirsen trial results

12-11-2013

Shares of US RNA-based drug developer Sarepta Therapeutics plummeted in pre-market trading on November…

BiotechnologydrisaperseneteplirsenGlaxoSmithKlineNorth AmericaRare diseasesRegulationResearchSarepta Therapeutics

Sarepta to file NDA for its Duchenne muscular dystrophy compound

25-07-2013

US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) plans to submit a New Drug Application…

BiotechnologyeteplirsenNorth AmericaRare diseasesRegulationSarepta Therapeutics

Back to top